Clinical Trial Update: Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating intratumoral Ulevostinag (MK-1454) in combination with intravenous pembrolizumab versus intravenous pembrolizumab alone as first-line…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Ulevostinag (MK-1454)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Status: COMPLETED | Results posted: 2023-10-27